Suppr超能文献

肝细胞癌患者的首发症状对预后的影响。

Prognostic impact of presenting symptoms of patients with hepatocellular carcinoma.

机构信息

Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore.

National Public Health and Epidemiology Unit, National Centre for Infectious Diseases, Singapore.

出版信息

Singapore Med J. 2024 Aug 1;65(8):444-448. doi: 10.4103/singaporemedj.SMJ-2021-283. Epub 2023 Apr 28.

Abstract

INTRODUCTION

It is not known if the nature, number and duration of presenting symptoms at diagnosis of hepatocellular carcinoma impact on overall survival. This study examines whether the presenting symptoms of hepatocellular carcinoma have a significant impact on prognosis.

METHODS

The study cohort comprised 725 patients with symptomatic hepatocellular carcinoma seen in our department since October 1983. Another 545 patients were diagnosed on surveillance or from incidental findings. Presenting symptoms at diagnosis were documented. A survival census was performed on 31 October 2015 with the national registry of deaths. Presenting symptoms were examined for association with overall survival using multivariable Cox regression analysis. Survival analysis was done by Kaplan-Meier method with log-rank testing. Bivariate Pearson correlation was used to look for any association between duration of symptoms and overall survival.

RESULTS

Patients with symptomatic hepatocellular carcinoma had a significantly shorter survival than those diagnosed incidentally or on screening (94.0 vs. 786.0 days, P < 0.001). Survival was shorter in patients presenting with fluid retention (56.0 vs. 118.0 days, P < 0.001), jaundice (48.0 vs. 94.0 days, P = 0.017) and two or more symptoms ( P = 0.010). Pain was associated with better survival ( P < 0.001). On multivariable Cox regression analysis, only fluid retention (hazard ratio [HR] 1.56, 95% confidence interval [CI] 1.30-1.87) and jaundice (HR 1.36, 95% CI 1.07-1.74) were independently associated with shorter survival. There was no significant relationship between the duration of symptoms and overall survival.

CONCLUSION

Patients with hepatocellular carcinoma who present with fluid retention or jaundice have significantly shorter overall survival. This is useful in assessing patients at the time of diagnosis.

摘要

简介

目前尚不清楚肝细胞癌诊断时出现的症状的性质、数量和持续时间是否会影响总生存期。本研究旨在探讨肝细胞癌的临床表现是否对预后有显著影响。

方法

本研究队列纳入了自 1983 年 10 月以来在我科就诊的有症状的肝细胞癌患者 725 例,另有 545 例患者在监测或偶然发现时被诊断为肝细胞癌。记录患者诊断时的临床表现。截至 2015 年 10 月 31 日,通过国家死亡登记处进行生存普查。采用多变量 Cox 回归分析,对所有表现症状与总生存期之间的关系进行了检查。采用 Kaplan-Meier 法进行生存分析,并进行对数秩检验。采用双变量 Pearson 相关分析,研究症状持续时间与总生存期之间是否存在任何关联。

结果

有症状的肝细胞癌患者的生存时间明显短于偶然诊断或筛查的患者(94.0 天 vs. 786.0 天,P < 0.001)。出现液体潴留(56.0 天 vs. 118.0 天,P < 0.001)、黄疸(48.0 天 vs. 94.0 天,P = 0.017)和两种或两种以上症状的患者( P = 0.010)的生存时间更短。疼痛与更好的生存相关(P < 0.001)。多变量 Cox 回归分析显示,只有液体潴留(危险比 [HR] 1.56,95%置信区间 [CI] 1.30-1.87)和黄疸(HR 1.36,95% CI 1.07-1.74)与较短的生存期独立相关。症状持续时间与总生存期之间无显著关系。

结论

出现液体潴留或黄疸的肝细胞癌患者的总生存期明显缩短。这在评估患者诊断时很有用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd20/11382824/db4472790035/SMJ-65-444-g001.jpg

相似文献

1
Prognostic impact of presenting symptoms of patients with hepatocellular carcinoma.
Singapore Med J. 2024 Aug 1;65(8):444-448. doi: 10.4103/singaporemedj.SMJ-2021-283. Epub 2023 Apr 28.
3
Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database.
BMC Cancer. 2021 Oct 29;21(1):1157. doi: 10.1186/s12885-021-08904-3.
4
Hepatocellular carcinoma in patients with chronic kidney disease.
World J Gastroenterol. 2013 Apr 28;19(16):2466-72. doi: 10.3748/wjg.v19.i16.2466.
5
Prognostic impact of diabetes mellitus on hepatocellular carcinoma: Special emphasis from the BCLC perspective.
PLoS One. 2017 Mar 23;12(3):e0174333. doi: 10.1371/journal.pone.0174333. eCollection 2017.
6
Analysis of prognostic factors of more/equal to10 years of survival for liver cancer patients after liver transplantation.
J Cancer Res Clin Oncol. 2018 Dec;144(12):2465-2474. doi: 10.1007/s00432-018-2756-8. Epub 2018 Sep 26.
8
Prognostic factors of spontaneously ruptured hepatocellular carcinoma.
World J Gastroenterol. 2015 Jun 28;21(24):7488-94. doi: 10.3748/wjg.v21.i24.7488.
9
Prognostic impact of concurrent nonalcoholic fatty liver disease in patients with chronic hepatitis B-related hepatocellular carcinoma.
J Gastroenterol Hepatol. 2020 Nov;35(11):1960-1968. doi: 10.1111/jgh.15026. Epub 2020 Mar 12.

本文引用的文献

1
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.
Int J Cancer. 2019 Apr 15;144(8):1941-1953. doi: 10.1002/ijc.31937. Epub 2018 Dec 6.
2
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.
J Hepatol. 2018 Jul;69(1):182-236. doi: 10.1016/j.jhep.2018.03.019. Epub 2018 Apr 5.
4
Associations among prognostic understanding, quality of life, and mood in patients with advanced cancer.
Cancer. 2014 Jan 15;120(2):278-85. doi: 10.1002/cncr.28369. Epub 2013 Oct 10.
5
Staging systems in hepatocellular carcinoma.
HPB (Oxford). 2005;7(1):35-41. doi: 10.1080/13651820410024058.
9
Hepatocellular carcinoma in Central Europe: prognostic features and survival.
Gut. 2001 Jan;48(1):103-9. doi: 10.1136/gut.48.1.103.
10
Improved survival with screening for hepatocellular carcinoma.
Liver Transpl. 2000 May;6(3):320-5. doi: 10.1053/lv.2000.4875.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验